• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶催化的受体裂解的细胞表面加速作用

Cell-surface acceleration of urokinase-catalyzed receptor cleavage.

作者信息

Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K

机构信息

Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.

出版信息

Eur J Biochem. 1997 Jan 15;243(1-2):21-6. doi: 10.1111/j.1432-1033.1997.0021a.x.

DOI:10.1111/j.1432-1033.1997.0021a.x
PMID:9030717
Abstract

The urokinase-type plasminogen activator (uPA) binds to a specific cell-surface receptor, uPAR. On several cell types uPAR is present both in the full-length form and a cleaved form, uPAR(2+3), which is devoid of binding activity. The formation of uPAR(2+3) on cultured U937 cells is either directly or indirectly mediated by uPA itself. In a soluble system, uPA can cleave purified uPAR, but the low efficiency of this reaction has raised doubts as to whether uPA is directly responsible for uPAR cleavage on the cells. We now report that uPA-catalyzed cleavage of uPAR on the cell surface is strongly favored relative to the reaction in solution. The time course of uPA-catalyzed cleavage of cell-bound uPAR was studied using U937 cells stimulated with phorbol 12-myristate 13-acetate. Only 30 min was required for 10 nM uPA to cleave 50% of the cell-bound uPAR. This uPA-catalyzed cleavage reaction was inhibited by a prior incubation of the cells with uPA inactivated by diisopropyl fluorophosphate, demonstrating a requirement for specific receptor binding of the active uPA to obtain the high-efficiency cleavage of cell-bound uPAR. Furthermore, amino-terminal sequence analysis revealed that uPAR(2+3), purified from U937 cell lysates, had the same amino termini as uPAR(2+3), generated by uPA in a purified system. In both cases cleavage had occurred at two positions in the hinge region connecting domain 1 and 2, between Arg83-Ala84 and Arg89-Ser90, respectively. The uPA-catalyzed cleavage of uPAR is a new negative-feedback regulation mechanism for cell-surface plasminogen activation. We propose that this mechanism plays a physiological role at specific sites with high local concentrations of uPA, thus adding another step to the complex regulation of this cascade reaction.

摘要

尿激酶型纤溶酶原激活剂(uPA)与一种特定的细胞表面受体uPAR结合。在几种细胞类型中,uPAR以全长形式和一种裂解形式uPAR(2 + 3)存在,后者缺乏结合活性。培养的U937细胞上uPAR(2 + 3)的形成要么直接由uPA本身介导,要么间接由其介导。在一个可溶性系统中,uPA可以裂解纯化的uPAR,但该反应效率较低,这引发了人们对uPA是否直接导致细胞上uPAR裂解的怀疑。我们现在报告,相对于溶液中的反应,uPA催化的细胞表面uPAR裂解受到强烈促进。使用佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯刺激的U937细胞研究了uPA催化的细胞结合型uPAR裂解的时间进程。10 nM的uPA仅需30分钟就能裂解50%的细胞结合型uPAR。用二异丙基氟磷酸使uPA失活后预先孵育细胞,可抑制这种uPA催化的裂解反应,这表明需要活性uPA进行特异性受体结合才能高效裂解细胞结合型uPAR。此外,氨基末端序列分析显示,从U937细胞裂解物中纯化的uPAR(2 + 3)与uPA在纯化系统中产生的uPAR(2 + 3)具有相同的氨基末端。在这两种情况下,裂解均发生在连接结构域1和2的铰链区的两个位置,分别在Arg83 - Ala84和Arg89 - Ser90之间。uPA催化的uPAR裂解是细胞表面纤溶酶原激活的一种新的负反馈调节机制。我们提出,这种机制在uPA局部浓度高的特定部位发挥生理作用,从而为这一级联反应的复杂调节增加了另一个步骤。

相似文献

1
Cell-surface acceleration of urokinase-catalyzed receptor cleavage.尿激酶催化的受体裂解的细胞表面加速作用
Eur J Biochem. 1997 Jan 15;243(1-2):21-6. doi: 10.1111/j.1432-1033.1997.0021a.x.
2
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.尿激酶型纤溶酶原激活剂切割其细胞表面受体,释放出配体结合结构域。
J Biol Chem. 1992 Sep 5;267(25):18224-9.
3
Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.人尿激酶型纤溶酶原激活剂与其受体的结合:涉及物种特异性和结合的残基。
Arterioscler Thromb Vasc Biol. 1998 May;18(5):693-701. doi: 10.1161/01.atv.18.5.693.
4
Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.纤溶酶原激活过程中尿激酶细胞受体的功能分析。受体结合对尿激酶原的酶原性质无影响。
J Biol Chem. 1996 Jun 21;271(25):14779-84. doi: 10.1074/jbc.271.25.14779.
5
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).环[19,31][D-半胱氨酸19]-尿激酶型纤溶酶原激活剂19-31是尿激酶型纤溶酶原激活剂与其受体(CD87)相互作用的强效竞争性拮抗剂。
Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150.
6
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.侵袭性移植的人源和鼠源肿瘤中尿激酶型纤溶酶原激活物受体的裂解形式。
Int J Cancer. 1994 Sep 15;58(6):877-81. doi: 10.1002/ijc.2910580622.
7
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.佛波酯肉豆蔻酸佛波醇酯对单核细胞样U937细胞中尿激酶受体的调节作用
J Cell Biol. 1989 Feb;108(2):693-702. doi: 10.1083/jcb.108.2.693.
8
Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.受体介导的纤溶酶原激活物功能调节:两种直接膜锚定形式的尿激酶对纤溶酶原的激活作用
J Pept Sci. 2000 Sep;6(9):432-9. doi: 10.1002/1099-1387(200009)6:9<432::AID-PSC279>3.0.CO;2-Q.
9
Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.整合素αvβ5介导的细胞迁移对受体结合型尿激酶型纤溶酶原激活剂的需求
J Biol Chem. 1996 Nov 15;271(46):29393-9. doi: 10.1074/jbc.271.46.29393.
10
A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.尿激酶生长因子结构域与2型纤溶酶原激活物抑制剂的杂合蛋白可抑制尿激酶活性,并与尿激酶受体结合。
Eur J Biochem. 1992 Jul 1;207(1):177-83. doi: 10.1111/j.1432-1033.1992.tb17035.x.

引用本文的文献

1
Urokinase Plasminogen Activator Receptor: An Important Focal Player in Chronic Subdural Hematoma?尿激酶型纤溶酶原激活物受体:慢性硬脑膜下血肿的重要焦点?
Inflammation. 2024 Jun;47(3):1015-1027. doi: 10.1007/s10753-023-01957-5. Epub 2024 Jan 18.
2
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.癌症中针对尿激酶及其受体的治疗策略
Cancers (Basel). 2022 Jan 19;14(3):498. doi: 10.3390/cancers14030498.
3
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.
以非侵入性成像和治疗干预为目的,针对人类疾病中的尿激酶型纤溶酶原激活物受体(uPAR)
Front Cell Dev Biol. 2021 Aug 20;9:732015. doi: 10.3389/fcell.2021.732015. eCollection 2021.
4
Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.血浆中尿激酶型纤溶酶原激活物受体的循环形式可预测膀胱尿路上皮癌患者的复发和生存情况。
Cancers (Basel). 2021 May 14;13(10):2377. doi: 10.3390/cancers13102377.
5
The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.尿激酶型纤溶酶原激活物受体:癌细胞生物学中的多功能受体。治疗意义。
Int J Mol Sci. 2021 Apr 16;22(8):4111. doi: 10.3390/ijms22084111.
6
Seroprevalence of /CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.危地马拉胃癌患者血清 /CagA 抗体的流行率:血清阳性与胃蛋白酶原血浆水平升高相关,但与可溶性尿激酶型纤溶酶原激活物受体无关。
Am J Trop Med Hyg. 2020 Jul;103(1):260-265. doi: 10.4269/ajtmh.19-0934. Epub 2020 Apr 16.
7
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.口腔癌细胞上尿激酶受体(uPAR)的裂解:转化生长因子-β1(TGF-β1)的调节作用及其对迁移和侵袭的潜在影响
BMC Cancer. 2017 May 19;17(1):350. doi: 10.1186/s12885-017-3349-7.
8
Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage.血浆可溶性尿激酶型纤溶酶原激活物受体与动脉瘤性蛛网膜下腔出血患者的神经功能结局无关。
Front Neurol. 2017 Apr 18;8:144. doi: 10.3389/fneur.2017.00144. eCollection 2017.
9
Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.尿激酶通过切割玻连蛋白中的RGD基序将纤溶酶原激活与细胞黏附联系起来。
EMBO Rep. 2016 Jul;17(7):982-98. doi: 10.15252/embr.201541681. Epub 2016 May 17.
10
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.转基因乳腺癌的自发性肺和淋巴结转移与尿激酶受体uPAR无关。
Clin Exp Metastasis. 2015 Aug;32(6):543-54. doi: 10.1007/s10585-015-9726-1. Epub 2015 Jun 4.